306 related articles for article (PubMed ID: 16497294)
1. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
[TBL] [Abstract][Full Text] [Related]
2. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
4. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
5. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
Bruins Slot LA; Palmier C; Tardif S; Cussac D
Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
[TBL] [Abstract][Full Text] [Related]
6. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
[TBL] [Abstract][Full Text] [Related]
7. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
8. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
Newman-Tancredi A; Assié MB; Leduc N; Ormière AM; Danty N; Cosi C
Int J Neuropsychopharmacol; 2005 Sep; 8(3):341-56. PubMed ID: 15707540
[TBL] [Abstract][Full Text] [Related]
9. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
10. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Bruins Slot LA; Kleven MS; Newman-Tancredi A
Neuropharmacology; 2005 Dec; 49(7):996-1006. PubMed ID: 16009387
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
[TBL] [Abstract][Full Text] [Related]
13. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
[TBL] [Abstract][Full Text] [Related]
14. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
[TBL] [Abstract][Full Text] [Related]
15. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Rauly-Lestienne I; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Cussac D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):93-105. PubMed ID: 17786406
[TBL] [Abstract][Full Text] [Related]
16. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
[TBL] [Abstract][Full Text] [Related]
17. SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.
Boulay D; Depoortere R; Louis C; Lacave M; Lucas MT; Griebel G
Pharmacol Biochem Behav; 2011 Jan; 97(3):428-35. PubMed ID: 20920519
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
19. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.
Boulay D; Depoortère R; Louis C; Perrault G; Griebel G; Soubrié P
Neuropharmacology; 2004 Jun; 46(8):1121-9. PubMed ID: 15111019
[TBL] [Abstract][Full Text] [Related]
20. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
